We’re glad to see you’re enjoying ReachMD…but how about a more personalized experience?
Exploring Developments in IgAN and FSGS
Howard Trachtman, MD, FASN
Richard Lafayette, MD, FACP
Addressing Issues of CV Mortality in Clinical Trials with IV Iron: Are We Still Getting a Medical Benefit?
Stefan D. Anker, MD, PhD
John Cleland, MD
Piotr Ponikowski, MD, PhD, FESC, FHFA
PROTECT Study in IgAN: Topline Data
Jonathan Barratt, MD
Hyperkalemia in CKD and HFrEF…What Am I Missing?
George L. Bakris, MD, FAHA, FASN
David Bushinsky, MD
Lars Lund, MD
The CKD Patient: Thinking Beyond the Numbers and Dialysis
Loreto Gesualdo, MD, FERA
David Jayne, MD
Carol Pollock, AO, MBBS, PhD, FRACP, FAHMS
Clinical Implications of the Evidence from IV Iron Trials in Heart Failure
Robert J. Mentz, MD, FHFSA, FACC, FAHA
Incorporating Targeted Therapies in Treatment Planning for AAV
Bernhard Hellmich, MD
What’s New About Gout? Nephrology Perspective
Abdul Abdellatif, MD, FASN
Richard Johnson, MD
What’s New About Gout? Rheumatology Perspective
John K. Botson, MD, RPh
Is Managing Gout in the Nephrology Clinic a Challenge?
The Underestimated Consequences of Uncontrolled Gout: Renal and Cardiovascular Implications
Brittany Weber, MD, PhD
Center of the Target: Which Patients Are Most Likely to Develop Gout?
What Are the Emerging Therapies for Managing Gout?
Can You Manage Patients With Uncontrolled Gout More Effectively?
Gout Beyond the Joints: What’s the Hidden Danger?
Press cancel to remain on ReachMD. Press the link below or the continue button to keep going.
Stay current with the best on medical education